TRACON Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
TRACON Pharmaceuticals has a total shareholder equity of $-1.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $9.4M and $11.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$7.89m |
| Equity | -US$1.76m |
| Total liabilities | US$11.12m |
| Total assets | US$9.36m |
Recent financial health updates
Recent updates
Tracon Pharmaceuticals announces $35M non-dilutive debt facility
Sep 06Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma
Aug 29Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M
Aug 10TRACON Pharmaceuticals announces $5M registered direct offering
Dec 29TRACON Pharma launches $8.8M direct offering
Dec 22Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study
Dec 10Tracon Pharma files China application for envafolimab in solid tumors
Nov 16Financial Position Analysis
Short Term Liabilities: TCON has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: TCON has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: TCON is debt free.
Reducing Debt: TCON's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: TCON has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: TCON has no debt, therefore coverage of interest payments is not a concern.